Scientists have discovered a compound capable of halting a common type of drug-resistant lung cancer. The researchers report that non-small cell lung cancers that had become invulnerable to the drugs Iressa and Tarceva were stymied by a new compound. The compound (WZ4002), whose basic chemical framework is different from that of other cancer drugs, acts against an epidermal growth factor receptor kinase that carries a specific structural defect.